Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (→‎L: added Lurbinectedin (Zepzelca))
Tag: visualeditor
Line 7: Line 7:
 
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.'''
 
'''Other [[#Interesting_and_Helpful_Links|interesting and helpful links]] can be found by clicking the link.'''
 
==Chemotherapy safety standards==
 
==Chemotherapy safety standards==
 +
 
*'''2020:''' Dillmon et al. [https://doi.org/10.1200/JCO.19.02297 Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards] [https://pubmed.ncbi.nlm.nih.gov/31815576 PubMed]
 
*'''2020:''' Dillmon et al. [https://doi.org/10.1200/JCO.19.02297 Patient-Centered Standards for Medically Integrated Dispensing: ASCO/NCODA Standards] [https://pubmed.ncbi.nlm.nih.gov/31815576 PubMed]
 
*'''2019:''' Celano et al. [https://doi.org/10.1200/JCO.18.01616 Safe handling of hazardous drugs: ASCO standards] [https://pubmed.ncbi.nlm.nih.gov/30620670 PubMed]
 
*'''2019:''' Celano et al. [https://doi.org/10.1200/JCO.18.01616 Safe handling of hazardous drugs: ASCO standards] [https://pubmed.ncbi.nlm.nih.gov/30620670 PubMed]
Line 13: Line 14:
  
 
==Dose adjustments==
 
==Dose adjustments==
 +
 
*'''2012:''' [http://jco.ascopubs.org/content/30/13/1553.long Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [http://jco.ascopubs.org/content/30/13/1553.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/22473167 PubMed]</ref>
 
*'''2012:''' [http://jco.ascopubs.org/content/30/13/1553.long Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [http://jco.ascopubs.org/content/30/13/1553.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/22473167 PubMed]</ref>
  
 
==Antimicrobials==
 
==Antimicrobials==
 +
 
*'''2013:''' [https://doi.org/10.1200/JCO.2012.45.8661 Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline]
 
*'''2013:''' [https://doi.org/10.1200/JCO.2012.45.8661 Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline]
  
 
==Growth factors==
 
==Growth factors==
 +
 
*'''2015:''' [http://jco.ascopubs.org/content/33/28/3199.full Update of ASCO Clinical Practice Guideline recommendations for the use of WBC growth factors]<ref>Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.</ref>
 
*'''2015:''' [http://jco.ascopubs.org/content/33/28/3199.full Update of ASCO Clinical Practice Guideline recommendations for the use of WBC growth factors]<ref>Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.</ref>
  
Line 28: Line 32:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Abarelix (Plenaxis)]]
 
*[[Abarelix (Plenaxis)]]
 
*[[Abciximab (ReoPro)]]
 
*[[Abciximab (ReoPro)]]
Line 65: Line 70:
 
*[[Amsacrine (Amsidine)]]
 
*[[Amsacrine (Amsidine)]]
 
*[[Anagrelide (Agrylin)]]
 
*[[Anagrelide (Agrylin)]]
−
*[[Anastrozole (Arimidex)]]  
+
*[[Anastrozole (Arimidex)]]
 
*[[Ancestim (Stemgen)]]
 
*[[Ancestim (Stemgen)]]
 
*[[Anti-inhibitor coagulant complex (FEIBA NF)]]
 
*[[Anti-inhibitor coagulant complex (FEIBA NF)]]
Line 86: Line 91:
 
*[[Aspirin and dipyridamole (Aggrenox)]]
 
*[[Aspirin and dipyridamole (Aggrenox)]]
 
*[[Astuprotimut-R (GSK1572932A)]] '''in clinical trials'''
 
*[[Astuprotimut-R (GSK1572932A)]] '''in clinical trials'''
−
*[[Atezolizumab (Tecentriq)]]  
+
*[[Atezolizumab (Tecentriq)]]
 
*[[Atropine (Atropen)]]
 
*[[Atropine (Atropen)]]
 
*[[Atovaquone (Mepron)]]
 
*[[Atovaquone (Mepron)]]
Line 102: Line 107:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Bacillus Calmette-Guérin (BCG)]]
 
*[[Bacillus Calmette-Guérin (BCG)]]
 
*[[Barasertib (AZD1152)]] '''in clinical trials'''
 
*[[Barasertib (AZD1152)]] '''in clinical trials'''
Line 111: Line 117:
 
*[[Belotecan (Camptobell)]]
 
*[[Belotecan (Camptobell)]]
 
*[[Bendamustine]]
 
*[[Bendamustine]]
−
*[[Benralizumab (Fasenra)]]  
+
*[[Benralizumab (Fasenra)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Betrixaban (Bevyxxa)]]
 
*[[Bevacizumab (Avastin)]]
 
*[[Bevacizumab (Avastin)]]
Line 138: Line 144:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Cabazitaxel (Jevtana)]]
 
*[[Cabazitaxel (Jevtana)]]
 
*[[Cabozantinib (Cabometyx)]]
 
*[[Cabozantinib (Cabometyx)]]
Line 197: Line 204:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Dabigatran (Pradaxa)]]
 
*[[Dabigatran (Pradaxa)]]
 
*[[Dabrafenib (Tafinlar)]]
 
*[[Dabrafenib (Tafinlar)]]
Line 253: Line 261:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Eculizumab (Soliris)]]
 
*[[Eculizumab (Soliris)]]
 
*[[Edoxaban (Savaysa)]]
 
*[[Edoxaban (Savaysa)]]
Line 290: Line 299:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Factor VIIa, recombinant (NovoSeven RT)]]
 
*[[Factor VIIa, recombinant (NovoSeven RT)]]
 
*[[Factor VIII, human]]
 
*[[Factor VIII, human]]
Line 337: Line 347:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Galeterone (TOK-001)]] '''in clinical trials'''
 
*[[Galeterone (TOK-001)]] '''in clinical trials'''
 
*[[Galunisertib (LY2157299)]] '''in clinical trials'''
 
*[[Galunisertib (LY2157299)]] '''in clinical trials'''
Line 348: Line 359:
 
*[[Glasdegib (Daurismo)]]
 
*[[Glasdegib (Daurismo)]]
 
*[[Glembatumumab vedotin (CDX-011)]]] '''in clinical trials'''
 
*[[Glembatumumab vedotin (CDX-011)]]] '''in clinical trials'''
−
*[[Glucarpidase (Voraxaze)]]  
+
*[[Glucarpidase (Voraxaze)]]
 
*[[Goserelin (Zoladex)]]
 
*[[Goserelin (Zoladex)]]
 
*[[Granisetron (Kytril)]]
 
*[[Granisetron (Kytril)]]
Line 360: Line 371:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Haloperidol (Haldol)]]
 
*[[Haloperidol (Haldol)]]
 
*[[Hematopoetic progenitor cells, cord blood (Hemacord)]]
 
*[[Hematopoetic progenitor cells, cord blood (Hemacord)]]
Line 374: Line 386:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Ibandronate (Boniva)]]
 
*[[Ibandronate (Boniva)]]
 
*[[Ibritumomab tiuxetan (Zevalin)]]
 
*[[Ibritumomab tiuxetan (Zevalin)]]
Line 410: Line 423:
  
 
==J==
 
==J==
 +
 
*[[JCAR015]] '''in clinical trials'''
 
*[[JCAR015]] '''in clinical trials'''
  
 
==K==
 
==K==
 +
 
*[[Ketoconazole (Nizoral)]]
 
*[[Ketoconazole (Nizoral)]]
  
Line 420: Line 435:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Lactulose]]
 
*[[Lactulose]]
 
*[[Lamivudine (Epivir)]]
 
*[[Lamivudine (Epivir)]]
Line 450: Line 466:
 
*[[Lorlatinib (Lorbrena)]]
 
*[[Lorlatinib (Lorbrena)]]
 
*[[Lorvotuzumab mertansine (BB-10901)]] '''in clinical trials'''
 
*[[Lorvotuzumab mertansine (BB-10901)]] '''in clinical trials'''
 +
*[[Lurbinectedin (Zepzelca)]] '''FDA approved 6/15/2020'''
 
*[[Luspatercept (Reblozyl)]] '''FDA approved 11/8/2019'''
 
*[[Luspatercept (Reblozyl)]] '''FDA approved 11/8/2019'''
 
*[[Lusutrombopag (Mulpleta)]]
 
*[[Lusutrombopag (Mulpleta)]]
Line 460: Line 477:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Mannitol]]
 
*[[Mannitol]]
 
*[[Mapatumumab (HGS-ETR1)]] '''in clinical trials'''
 
*[[Mapatumumab (HGS-ETR1)]] '''in clinical trials'''
Line 498: Line 516:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Nabilone (Cesamet)]]
 
*[[Nabilone (Cesamet)]]
 
*[[Necitumumab (Portrazza)]]
 
*[[Necitumumab (Portrazza)]]
Line 503: Line 522:
 
*[[Nelarabine (Arranon)]]
 
*[[Nelarabine (Arranon)]]
 
*[[NEOD001]]
 
*[[NEOD001]]
−
*[[Neratinib (Nerlynx)]]  
+
*[[Neratinib (Nerlynx)]]
 
*[[Netupitant and palonosetron (Akynzeo)]]
 
*[[Netupitant and palonosetron (Akynzeo)]]
 
*[[Nilotinib (Tasigna)]]
 
*[[Nilotinib (Tasigna)]]
Line 521: Line 540:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Obinutuzumab (Gazyva)]]
 
*[[Obinutuzumab (Gazyva)]]
 
*[[Octreotide (Sandostatin)]]
 
*[[Octreotide (Sandostatin)]]
Line 546: Line 566:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Paclitaxel (Taxol)]]
 
*[[Paclitaxel (Taxol)]]
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
Line 604: Line 625:
  
 
==Q==
 
==Q==
 +
 
*[[Quinine (Qualaquin)]]
 
*[[Quinine (Qualaquin)]]
 
*[[Quisinostat (JNJ-26481585)]] '''in clinical trials'''
 
*[[Quisinostat (JNJ-26481585)]] '''in clinical trials'''
Line 613: Line 635:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Rabeprazole (Aciphex)]]
 
*[[Rabeprazole (Aciphex)]]
 
*[[Radium Ra 223 (Xofigo)]]
 
*[[Radium Ra 223 (Xofigo)]]
Line 655: Line 678:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Sacituzumab govitecan (Trodelvy)]] '''FDA approved 4/22/2020'''
 
*[[Sacituzumab govitecan (Trodelvy)]] '''FDA approved 4/22/2020'''
 
*[[Samarium-153 (Quadramet)]]
 
*[[Samarium-153 (Quadramet)]]
Line 686: Line 710:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Tabalumab (LY2127399)]] '''in clinical trials'''
 
*[[Tabalumab (LY2127399)]] '''in clinical trials'''
 
*[[Tacrolimus (Prograf)]]
 
*[[Tacrolimus (Prograf)]]
Line 748: Line 773:
  
 
==U==
 
==U==
 +
 
*[[Ublituximab (TG-1101)]] '''in clinical trials'''
 
*[[Ublituximab (TG-1101)]] '''in clinical trials'''
 
*[[Umbralisib (TGR-1202)]] '''in clinical trials'''
 
*[[Umbralisib (TGR-1202)]] '''in clinical trials'''
Line 760: Line 786:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Vadastuximab talirine (SGN-CD33A)]] '''in clinical trials'''
 
*[[Vadastuximab talirine (SGN-CD33A)]] '''in clinical trials'''
 
*[[Valacyclovir (Valtrex)]]
 
*[[Valacyclovir (Valtrex)]]
Line 767: Line 794:
 
*[[Vandetanib (Caprelsa)]]
 
*[[Vandetanib (Caprelsa)]]
 
*[[Varlilumab (CDX-1127)]] '''in clinical trials'''
 
*[[Varlilumab (CDX-1127)]] '''in clinical trials'''
−
*[[Veliparib (ABT-888)]] '''in clinical trials'''  
+
*[[Veliparib (ABT-888)]] '''in clinical trials'''
 
*[[Veltuzumab (hA20)]] '''in clinical trials'''
 
*[[Veltuzumab (hA20)]] '''in clinical trials'''
 
*[[Vemurafenib (Zelboraf)]]
 
*[[Vemurafenib (Zelboraf)]]
Line 793: Line 820:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Warfarin (Coumadin)]]
 
*[[Warfarin (Coumadin)]]
  
 
==Z==
 
==Z==
 +
 
*[[Zanubrutinib (Brukinsa)]] '''FDA approved 11/14/2019'''
 
*[[Zanubrutinib (Brukinsa)]] '''FDA approved 11/14/2019'''
 
*[[Ziv-aflibercept (Zaltrap)]]
 
*[[Ziv-aflibercept (Zaltrap)]]
Line 810: Line 839:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Alkylating agents|Alkylating agents]]
 
*[[:Category:Alkylating agents|Alkylating agents]]
 
*[[:Category:Anthracyclines|Anthracyclines]]
 
*[[:Category:Anthracyclines|Anthracyclines]]
Line 865: Line 895:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Antiandrogens|Antiandrogens]]
 
*[[:Category:Antiandrogens|Antiandrogens]]
 
*[[:Category:Steroid synthesis inhibitors|Steroid synthesis inhibitors]]
 
*[[:Category:Steroid synthesis inhibitors|Steroid synthesis inhibitors]]
Line 877: Line 908:
  
 
==Investigational and Discontinued==
 
==Investigational and Discontinued==
 +
 
*[[:Category:Investigational_drugs|Investigational]]
 
*[[:Category:Investigational_drugs|Investigational]]
 
*[[:Category:Discontinued_drugs|Discontinued]]
 
*[[:Category:Discontinued_drugs|Discontinued]]
Line 885: Line 917:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Antibody medications|Antibody medications]]
 
*[[:Category:Antibody medications|Antibody medications]]
 
*[[:Category:Antibody-drug conjugates|Antibody-drug conjugates]]
 
*[[:Category:Antibody-drug conjugates|Antibody-drug conjugates]]
Line 898: Line 931:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Antibacterials|Antibacterials]]
 
*[[:Category:Antibacterials|Antibacterials]]
 
*[[:Category:Antidiarrheals|Antidiarrheals]]
 
*[[:Category:Antidiarrheals|Antidiarrheals]]
Line 911: Line 945:
  
 
==[[:Category:Radioactive agents|Radioactive agents]]==
 
==[[:Category:Radioactive agents|Radioactive agents]]==
 +
 
*[[:Category:Alpha emitters|Alpha emitters]]
 
*[[:Category:Alpha emitters|Alpha emitters]]
 
*[[:Category:Radioimmunotherapy|Radioimmunotherapy]]
 
*[[:Category:Radioimmunotherapy|Radioimmunotherapy]]
Line 919: Line 954:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Anticoagulants|Anticoagulants]]
 
*[[:Category:Anticoagulants|Anticoagulants]]
 
**[[:Category:Direct thrombin inhibitors|Direct thrombin inhibitors (DTI)]]
 
**[[:Category:Direct thrombin inhibitors|Direct thrombin inhibitors (DTI)]]
Line 940: Line 976:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]]
 
*[[:Category:Erythrocyte growth factors|Erythrocyte growth factors]]
 
*[[:Category:Granulocyte colony-stimulating factors|Granulocyte growth factors]]
 
*[[:Category:Granulocyte colony-stimulating factors|Granulocyte growth factors]]
Line 949: Line 986:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:REMS_program|Drugs in a REMS program]]
 
*[[:Category:REMS_program|Drugs in a REMS program]]
 
*[[:Category:HDAC inhibitors|HDAC inhibitors]]
 
*[[:Category:HDAC inhibitors|HDAC inhibitors]]
Line 968: Line 1,006:
 
*[[:Category:Basal cell and squamous cell skin cancer medications|Basal cell and squamous cell skin cancer medications]]
 
*[[:Category:Basal cell and squamous cell skin cancer medications|Basal cell and squamous cell skin cancer medications]]
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
 
*[[:Category:Bladder cancer medications|Bladder cancer medications]]
−
*[[:Category:Bone cancer medications |Bone cancer medications]]  
+
*[[:Category:Bone cancer medications |Bone cancer medications]]
 
*[[:Category:Breast cancer medications|Breast cancer medications]]
 
*[[:Category:Breast cancer medications|Breast cancer medications]]
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
 
*[[:Category:Burkitt lymphoma medications|Burkitt lymphoma medications]]
−
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]  
+
*[[:Category:Cancer of unknown primary medications |Cancer of unknown primary medications]]
 
*[[:Category:Castleman’s disease medications|Castleman’s disease medications]]
 
*[[:Category:Castleman’s disease medications|Castleman’s disease medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
 
*[[:Category:Central nervous system (CNS) cancer medications|Central nervous system (CNS) cancer medications]]
Line 999: Line 1,037:
 
*[[:Category:Marginal zone lymphoma medications|Marginal zone lymphoma medications]]
 
*[[:Category:Marginal zone lymphoma medications|Marginal zone lymphoma medications]]
 
*[[:Category:Mediastinal gray-zone lymphoma medications|Mediastinal gray-zone lymphoma medications]]
 
*[[:Category:Mediastinal gray-zone lymphoma medications|Mediastinal gray-zone lymphoma medications]]
−
*[[:Category:Melanoma medications |Melanoma medications]]  
+
*[[:Category:Melanoma medications |Melanoma medications]]
 
*[[:Category:Mesothelioma medications|Mesothelioma medications]]
 
*[[:Category:Mesothelioma medications|Mesothelioma medications]]
 
*[[:Category:Multiple myeloma medications|Multiple myeloma medications]]
 
*[[:Category:Multiple myeloma medications|Multiple myeloma medications]]
Line 1,008: Line 1,046:
 
*[[:Category:Neuroendocrine tumor medications|Neuroendocrine tumor medications]]
 
*[[:Category:Neuroendocrine tumor medications|Neuroendocrine tumor medications]]
 
*[[:Category:Ovarian cancer medications|Ovarian cancer medications]]
 
*[[:Category:Ovarian cancer medications|Ovarian cancer medications]]
−
*[[:Category:Pancreatic cancer medications |Pancreatic cancer medications]]  
+
*[[:Category:Pancreatic cancer medications |Pancreatic cancer medications]]
 
*[[:Category:Paroxysmal nocturnal hemoglobinuria medications|Paroxysmal nocturnal hemoglobinuria (PNH) medications]]
 
*[[:Category:Paroxysmal nocturnal hemoglobinuria medications|Paroxysmal nocturnal hemoglobinuria (PNH) medications]]
−
*[[:Category:Penile cancer medications |Penile cancer medications]]  
+
*[[:Category:Penile cancer medications |Penile cancer medications]]
 
*[[:Category:Peripheral T-cell lymphoma medications|Peripheral T-cell lymphoma medications]]
 
*[[:Category:Peripheral T-cell lymphoma medications|Peripheral T-cell lymphoma medications]]
 
*[[:Category:Plasma cell leukemia medications|Plasma cell leukemia medications]]
 
*[[:Category:Plasma cell leukemia medications|Plasma cell leukemia medications]]
Line 1,018: Line 1,056:
 
*[[:Category:Rectal cancer medications|Rectal cancer medications]]
 
*[[:Category:Rectal cancer medications|Rectal cancer medications]]
 
*[[:Category:Renal cell carcinoma medications|Renal cell carcinoma medications]]
 
*[[:Category:Renal cell carcinoma medications|Renal cell carcinoma medications]]
−
*[[:Category:Sarcoma medications |Sarcoma medications]]  
+
*[[:Category:Sarcoma medications |Sarcoma medications]]
 
*[[:Category:Sickle cell anemia medications|Sickle cell anemia medications]]
 
*[[:Category:Sickle cell anemia medications|Sickle cell anemia medications]]
 
*[[:Category:Small cell lung cancer medications|Small cell lung cancer medications]]
 
*[[:Category:Small cell lung cancer medications|Small cell lung cancer medications]]
Line 1,035: Line 1,073:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[:Category:Intra-arterial medications|Intraarterial (IA) medications]]
 
*[[:Category:Intra-arterial medications|Intraarterial (IA) medications]]
 
*[[:Category:Intracavitary medications|Intracavitary medications]]
 
*[[:Category:Intracavitary medications|Intracavitary medications]]
Line 1,127: Line 1,166:
 
|[[#top|back to top]]
 
|[[#top|back to top]]
 
|}
 
|}
 +
 
*[[Antidepressants and other psychiatric medications in cancer care]]
 
*[[Antidepressants and other psychiatric medications in cancer care]]
 
*[[Antiemesis|Antiemetic support]]
 
*[[Antiemesis|Antiemetic support]]
Line 1,148: Line 1,188:
  
 
==References==
 
==References==
−
<references/>
+
<references />
  
 
[[Category:General reference pages]]
 
[[Category:General reference pages]]
 
[[Category:Clinical pharmacology]]
 
[[Category:Clinical pharmacology]]

Revision as of 20:07, 19 November 2020

Guidelines

back to top

Other interesting and helpful links can be found by clicking the link.

Chemotherapy safety standards

Dose adjustments

Antimicrobials

Growth factors

Alphabetically

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Condition

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  2. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
  3. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
  4. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  5. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=46608"